Industry
Roche Scales NVIDIA AI Factories for Global Drug Discovery
Roche Embraces AI Factories for Next-Gen Drug Discovery and Manufacturing
Healthcare giant Roche is making a significant leap in its digital transformation, announcing a massive deployment of over 3,500 NVIDIA Blackwell GPUs. This move establishes what is reportedly the greatest announced GPU footprint available to a pharmaceutical company, poised to revolutionize drug discovery, diagnostic solutions, and manufacturing processes worldwide. The new AI computing backbone will span hybrid cloud and on-premises environments across the U.S. and Europe, signaling a new era for AI in healthcare.
What's Happening: A Foundation for Future Healthcare
Roche's strategic investment in NVIDIA's cutting-edge AI infrastructure is set to supercharge its capabilities across the entire value chain. This new backbone will power critical areas, from developing biological foundation models and accelerating drug discovery to creating sophisticated digital twins for manufacturing. The aim is clear: to embed AI and accelerated computing as core operational capabilities, driving unprecedented R&D productivity and manufacturing efficiencies.
Accelerating Discovery: AI at the Heart of R&D
The impact of this deployment on drug discovery is immense. Roche and its biotechnology arm, Genentech, are already seeing significant benefits from integrating AI into their research. Nearly 90% of Genentech’s eligible small-molecule programs now integrate AI, demonstrating its central role.
Concrete examples highlight the speed and efficiency gains:
- AI helped design a degrader molecule for oncology 25% faster.
- A backup drug candidate, a crucial safety net in drug development, was delivered in just seven months—a process that typically takes over two years.
To achieve these breakthroughs, Roche is leveraging NVIDIA Blackwell GPUs alongside the NVIDIA BioNeMo platform. This powerful combination allows scientists to train and fine-tune biological and molecular foundation models, integrate proprietary datasets, and expand AI-driven lab automation, accelerating the entire "Lab-in-the-Loop" strategy.
Revolutionizing Manufacturing with Digital Twins
Beyond the lab, Roche is also modernizing its pharmaceutical manufacturing processes using NVIDIA Omniverse libraries. By building high-fidelity digital twins of production facilities, the company can simulate and optimize complex systems before they go live. An excellent example is the acceleration of the development of Roche’s new GLP-1 manufacturing facility in North Carolina, where virtual environments are playing a crucial role. This approach promises to streamline operations, reduce risks, and enhance efficiency across its global supply chain.
Boosting Diagnostics and Digital Health
The innovations extend to Roche's diagnostics business and digital health portfolio. Accelerated computing and NVIDIA Parabricks software enable profound insights across vast datasets, helping to detect subtle disease patterns and improve diagnostic accuracy. For digital health applications, Roche employs NVIDIA NeMo to ensure safe and reliable healthcare-grade AI, further enhancing clinical decision support and patient outcomes.
Why It Matters: A Faster Path to Patient Care
This massive scaling of AI infrastructure by Roche isn't just a technological upgrade; it's a commitment to accelerating the delivery of life-saving medicines and diagnostics to patients worldwide. By making accelerated computing a core capability across its global organization, Roche is transforming AI from a specialized discipline into an everyday tool for scientific and clinical workflows. This means more viable drug targets, faster therapeutic development, more efficient manufacturing, and new forms of precision medicine. The deployment lays the foundation for Roche's next decade of innovation, promising significant advancements for the entire healthcare continuum.
AI's Broader Impact: Beyond Healthcare
The trend of integrating advanced AI infrastructure is rapidly expanding across industries. Just as Roche is building AI factories for drug discovery, other sectors are also establishing robust AI grids. For instance, the telecommunications industry is also building AI grids to optimize inference on distributed networks, highlighting the universal demand for accelerated computing to power AI-native applications at scale.
Read more: Discover how Roche is leveraging NVIDIA AI Factories for global drug discovery and more on the NVIDIA Blog.